Lamivudine for the treatment of hepatitis B virus reactivation following chemotherapy for non-Hodgkin's lymphoma
Open Access
- 1 January 2002
- journal article
- research article
- Published by Wiley in British Journal of Haematology
- Vol. 116 (1) , 166-169
- https://doi.org/10.1046/j.1365-2141.2002.03239.x
Abstract
No abstract availableKeywords
This publication has 9 references indexed in Scilit:
- Lamivudine allows completion of chemotherapy in lymphoma patients with hepatitis B reactivationBritish Journal of Haematology, 2000
- Long-term follow-up of patients with anti-HBe/HBV DNA-positive chronic hepatitis B treated for 12 months with lamivudineJournal of Hepatology, 2000
- Prevention of hepatitis B flare-up during chemotherapy using lamivudine: case report and review of the literatureAnnals of Hematology, 1999
- A One-Year Trial of Lamivudine for Chronic Hepatitis BNew England Journal of Medicine, 1998
- Successful treatment with lamivudine for fulminant reactivated hepatitis B infection following intensive therapy for high-grade non-Hodgkin’s lymphomaAnnals of Oncology, 1998
- A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group [see comments]Blood, 1994
- Reactivation of hepatitis B virus replication in patients receiving cytotoxic therapyPublished by Elsevier ,1991
- Hepatitis B infection in patients with lymphomasHematological Oncology, 1990
- Hepatitis-Associated Antigen and Hepatocellular Carcinoma in TaiwanAnnals of Internal Medicine, 1971